BofA raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $90 from $88 and keeps a Buy rating on the shares after a revenue beat in Q4 and management providing full-year revenue guidance for the first time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
- Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
- Tarsus: Raising Peak Xdemvy Outlook to $2B+ on Strong Q4 Momentum and Pipeline Upside
- Tarsus Pharmaceuticals reports Q4 EPS (20c), consensus (13c)
- TARS Upcoming Earnings Report: What to Expect?